Zixing AI Files IPO Prospectus: Pioneering AI-Powered Chromosome Karyotype Analysis in Genetic Reproduction and Hematologic Oncology

“The Innovator’s Prescription” mentions that opportunities for disruptive innovation are hidden in niche markets on the fringe, which are overlooked by industry leaders.

“AI-based karyotype analysis represents a niche market within the currently crowded medical AI sector. Starting from this ‘unpopular’ niche, continuously strengthening competitiveness, and gradually penetrating toward the market center is also the strategic development logic of ZIXING AI,” said Cai Yufeng.

Cai Yufeng is a successful serial entrepreneur. E-commerce, autonomous driving, medical AI... Cai Yufeng always stays one step ahead, entering these fields before they become hotspots.

ZIXING AI was established in Changsha in December 2016. Unlike most AI companies, ZIXING AI did not opt for popular AI healthcare application scenarios such as pulmonary nodule detection, cervical cancer screening, or fundus examination; instead, it chose the niche field of AI-based chromosome karyotype analysis. Judging by ZIXING AI’s current growth trajectory, this strategic choice has yielded positive results.

Over the past four years since its establishment, ZIXING AI has completed two rounds of financing and invested nearly RMB 100 million in the niche sector of AI-based chromosome karyotype analysis.

Currently, ZIXING AI’s AI-based chromosome karyotyping analysis system has been deployed in over 10 leading benchmark hospitals, including CITIC-Xiangya Reproductive and Genetic Hospital and the First Affiliated Hospital of Zhengzhou University, achieving business substitution for traditional chromosome analysis.

ZIXING AI, the company’s name, is derived from its Chief Scientist, Cai Zixing. Professor Cai Zixing served as Vice President of the Chinese Association for Artificial Intelligence during its 3rd and 4th Councils, is an IEEE Life Fellow, and holds a professorship at Central South University. With 35 years of dedication to research in intelligent science and technology, he has specialized in artificial intelligence and intelligent robotics, authored and published over 50 academic books in the field of AI, and presented more than 1,000 academic papers both domestically and internationally.

As the inaugural recipient of the National Teaching Master Award for Chinese universities, Cai Zixing is dedicated to cultivating more talent aspiring to work in artificial intelligence. In contrast to his father’s focus on AI academia and scientific research, Cai Yufeng, founder of ZIXING AI, places greater emphasis on AI applications and industrialization.

After graduating from Central South University of Technology, Cai Yufeng joined Lenovo Group, a Fortune Global 500 company. Over nearly a decade, he rapidly advanced from an entry-level position to become Marketing Director for Lenovo’s Guangdong Region and Assistant to the President of Lenovo Group, earning a place among the inaugural “Lenovo Top 50 Elites.” During this period, he also completed an Executive MBA (EMBA) at the Hong Kong University of Science and Technology. He subsequently embarked on an independent entrepreneurial venture in the e-commerce sector, where he earned his first significant fortune. To date, Mr. Cai has accumulated over 20 years of business experience and more than 10 years of entrepreneurial expertise, thereby amassing substantial resources and experience for his second entrepreneurial venture in the field of artificial intelligence.

In 2014, Cai Zixing received the Achievement Award of the Wu Wenjun Intelligent Science and Technology Award, the highest honor in artificial intelligence in China. Seizing this opportunity, Cai Yufeng decided to return to the AI field, dedicating himself to commercializing his father’s research achievements accumulated over more than three decades.

Benefiting from Cai Zixing’s influence in the industry, the ZIXING AI team has rapidly assembled a group of high-caliber professionals in the field of artificial intelligence, most of whom were once mentored by Cai Zixing. Furthermore, Cai Yufeng places significant emphasis on the team’s engineering capabilities and has intentionally recruited top engineering talent from Huawei during the selection process. As a result, the core team of ZIXING AI bears strong affiliations with both Central South University and Huawei.

2017 marked a significant milestone in the development of ZIXING AI. While providing services to CITIC-Xiangya Hospital, ZIXING AI encountered the specialized application scenario of karyotype analysis.

Chromosome Karyotype AnalysisChromosome karyotype analysis focuses on chromosomes at metaphase. Based on characteristics such as chromosome length, centromere position, the ratio of long to short arms, and the presence or absence of satellites, this technique employs banding methods to analyze, compare, arrange, and number chromosomes, thereby facilitating diagnosis according to variations in chromosomal structure and number. To date, nearly 10,000 types of human chromosomal numerical abnormalities and structural aberrations have been identified, along with more than 100 chromosomal disorder syndromes. Chromosomal disorders have become one of the most common causes of spontaneous abortion and birth defects, accounting for an incidence rate of 50%. This technology is now widely applied in hospital departments including clinical laboratories, hematology, obstetrics and gynecology, reproductive centers, as well as in family planning research institutes, occupational disease prevention and control institutes, universities, and scientific research institutions.

Although karyotyping has been utilized for decades, this technique still faces significant challenges and pain points that urgently need to be addressed.

First, there is a scarcity of specialized talent. Training a proficient human chromosome researcher takes at least three years, and the transfer of clinical experience relies heavily on mentorship and hands-on instruction, resulting in high training costs. Second, regarding clinical analysis, existing auxiliary tools exhibit low levels of intelligence; each case requires approximately 30–50 minutes for analysis, leading to low efficiency.

Addressing these pain points, ZIXING AI leveraged its technological strengths to tackle AI-based chromosome karyotype analysis. However, proving easier said than done, the journey from a preliminary AI algorithm to a mature medical AI product required overcoming countless obstacles and resolving numerous issues—a process that kept the ZIXING AI team engaged for over three years.

ZIXING AI’s AI-powered chromosome karyotyping system, tested on over 4 million chromosome images, achieves an automated recognition accuracy rate exceeding 98%. It compresses a workload that originally required 25 days into just one day, reducing labor by more than 70%. To date, the system has issued over 100,000 auxiliary diagnostic reports and has replaced conventional workflows in more than ten leading benchmark hospitals.

ZIXING AI has secured 22 invention patents and one PCT patent, establishing an initial intellectual property moat. By the end of 2020, its ZIXING Intelligent Karyotype Analysis System obtained registration as a Class II medical device, while its independently developed chromosome scanner had entered internal testing phases. Moving forward, ZIXING AI will focus on karyotype analysis to gradually integrate the entire chromosome industry chain, providing healthcare clients with the most professional and comprehensive intelligent karyotype analysis technical services.

In the course of continuously deepening the application of AI technology to chromosome karyotype analysis, several top-tier international medical institutions approached ZIXING AI. During communications with these institutions, ZIXING AI was pleasantly surprised to discover that chromosome karyotype analysis also represents a significant pain point in tumor analysis. Chromosomal abnormalities are present in nearly all tumor cells and are considered one of the hallmark features of cancer cells.

Chromosomal karyotype abnormalities are closely associated with the initiation and progression of tumors, providing a robust theoretical foundation for the ZIXING AI Chromosome System to serve as a tool for screening and analytical assessment of cancer cells.

The integration of artificial intelligence facilitates in-depth analysis of chromosomal karyotypes in the differential diagnosis of tumors, assessment of drug resistance, and prognosis evaluation, thereby expanding new horizons for research into tumorigenesis mechanisms and providing novel insights into tumor diagnosis, classification, treatment, and prognosis.

At the end of 2020, ZIXING AI initiated a collaboration with a world-leading hematology team. Cai Yufeng revealed that ZIXING AI plans to launch the first version of its auxiliary system for chromosomal karyotyping in hematologic malignancies by the end of 2021.

Cai Yufeng believes that healthcare is an industry that demands meticulous, long-term effort, requiring immense patience and perseverance. To this end, ZIXING AI will focus on the field of intelligent chromosome analysis, striving to “dig one kilometer deep within a one-square-meter area.” The company aims to become the “BGI Genomics” of the chromosome sector within ten years. Currently, ZIXING AI is undertaking a new round of financing to support product R&D, acquisition of medical device certifications, laboratory construction, and market expansion.